Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors

BACKGROUND AND PURPOSE: Metastatic renal cell carcinoma (MRCC) has a poor prognosis with a median overall survival of about one year. Since only a minority of patients experienced therapeutic benefit to current treatments, several studies have attempted to identify factors that may have an impact on...

Descripción completa

Detalles Bibliográficos
Autores principales: Guida, Michele, Casamassima, Addolorata, Monticelli, Giulia, Quaranta, Michele, Colucci, Giuseppe
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2169206/
https://www.ncbi.nlm.nih.gov/pubmed/17953739
http://dx.doi.org/10.1186/1479-5876-5-51

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2169206/
https://www.ncbi.nlm.nih.gov/pubmed/17953739
http://dx.doi.org/10.1186/1479-5876-5-51

Ejemplares similares